In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck KGAA teams up with OncoMethylome for companion cancer diagnostic

Executive Summary

OncoMethylome Sciences SA (molecular diagnostics) has licensed Merck KGAA nonexclusive worldwide rights to an assay for use with Merck’s integrin inhibitor cilengitide, a Phase III therapeutic compound for glioblastoma multiforme (GBM), the most aggressive and malignant type of brain tumor.
Deal Industry
  • In Vitro Diagnostics
  • Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies